Article
Merck's HPV Vaccine Effective Against 9 Subtypes
The study, conducted in Austria, evaluated the potency of the 9-valent vaccine in preventing the development of cervical precancer in women infected with HPV.
An experimental vaccine meant to protect against 9 types of human papillomavirus (HPV) could prevent 90 percent of all cervical cancers, a new study suggests.
Researchers examined data from more than 2,500 women with precancerous cervical lesions and found that nearly all were caused by the nine types of HPV targeted by the vaccine being developed by Merck and Co.
Cancer Epidemiology, Biomarkers & Prevention
The new vaccine, currently undergoing clinical trials, protects against more types of HPV than current vaccines, according to the study published Oct. 1 in the journal .
Report on MedicalXpress: http://bit.ly/1rMstbg
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
